-013

VOLUME ONE HUNDRED AND FORTY ONE

INTERNATIONAL REVIEW OF NEUROBIOLOGY

Imaging in Movement Disorders: Imaging Methodology and Applications in Parkinson's Disease

Edited by

MARIOS POLITIS, MD MSc DIC PhD FRCP FEAN

Professor of Neurology & Neuroimaging
Director, Neurodegeneration Imaging Group,
Institute of Psychiatry, Psychology and Neuroscience,
King's College London, United Kingdom

Mahidol University
Faculty of Science
Stang Mongkolsuk Library and Information Division

ACADEMIC PRESS
An imprint of Elsevier

CONTENTS

Contributors *xi*
Preface *xv*
Acknowledgement *xvii*

Section 1
Imaging Methodology

1. Advances in PET Methodology **3**

Vesna Sossi

1. Introduction 4
2. PET Tracers Relevant to Movement Disorders 6
3. Basic PET Principles and Traditional Kinetic Analyses 11
4. Algorithmic Advances in PET 13
5. Connectivity Analysis Methods: FDG and Other Tracers 17
6. Hybrid PET/MRI 20
7. Conclusion 21

References 22

2. Advances in MRI Methodology **31**

Tayyabah Yousaf, George Dervenoulas, and Marios Politis

1. Introduction 32
2. Magnetic Resonance Imaging Hardware 32
3. Image Acquisition 35
4. Magnetic Resonance Imaging Applications 43
5. Final Remarks 65

References 65

3. Advances in SPECT Methodology **77**

Alberto Cuocolo, Sabina Pappatà, Emilia Zampella, and Roberta Assante

1. Introduction 78
2. Molecular Targets 79
3. SPECT Systems 84
4. Hybrid SPECT/CT 91

References 92

4. Hybrid PET/MRI Methodology **97**

Marco Aiello, Carlo Cavaliere, Rocco Marchitelli, Antonio d'Albore, Enrico De Vita, and Marco Salvatore

1. Introduction 98
2. Integrating PET and MR imaging 98
3. Open Challenges and Technological Applications 104
4. Final Remarks 119

Acknowledgment 120
References 120
Further Reading 128

Section 2
Imaging Applications in Parkinson's Disease

5. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease **131**

Edoardo R. de Natale, Flavia Niccolini, Heather Wilson, and Marios Politis

1. Introduction 132
2. Imaging of Presynaptic Dopaminergic System 136
3. Imaging of Postsynaptic Dopaminergic System 142
4. Motor Complications 146
5. Non-motor Symptoms 152
6. Neuroplasticity 158
7. Conclusions 159

References 159

6. Molecular Imaging of the Serotonergic System in Parkinson's Disease **173**

Gennaro Pagano and Marios Politis

1. Introduction 174
2. Molecular Imaging Techniques to Study Serotonergic System Changes in Parkinson's Disease 175
3. Serotonergic System Changes in Parkinson's Disease 184
4. Serotonergic System Changes and Motor Symptoms in Parkinson's Disease 186
5. Serotonergic System Changes and Non-motor Symptoms in Parkinson's Disease 193
6. Serotonergic System Changes in Asymptomatic LRRK2 Carriers: Compensation, or Different Pathology? 199

7. Conclusions and Future Directions 201
Acknowledgments 202
References 202
Further Reading 210

7. Molecular Imaging of the Cholinergic System in Parkinson's Disease 211

Nicolaas I. Bohnen, Prabesh Kanel, and Martijn L.T.M. Müller

1. Introduction 212
2. Molecular Imaging Techniques to Study Cholinergic System Changes in PD 214
3. Cholinergic System Changes in PD and Parkinsonian Dementia 219
4. Mobility Impairments: Falls, Gait Speed, Freezing of Gait and Postural Control 229
5. Dyskinesias 231
6. Olfaction 231
7. Sleep 232
8. Depression 233
9. Visual Hallucinations 233
10. Fatigue 234
11. Risk Taking Behavior and Driving in Patients With PD 234
12. Peripheral Cholinergic Autonomic Organ Changes in PD 235
13. Hypercholinergic System Findings in Prodromal Leucine-Rich Repeat Kinase 2 PD: Compensation, Microglial Inflammation or Both? 236
14. Discussion 237
15. Conclusions and Future Directions 240

Acknowledgments 241
Disclaimer 241
Competing Interests 241
References 241

8. Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease 251

Adjmal Nahimi, Martin B. Kinnerup, Michael Sommerauer, Albert Gjedde, and Per Borghammer

1. Introduction to the Noradrenaline System 252
2. Non-Motor Symptoms and Noradrenaline Deficits in Parkinson's Disease 253
3. Molecular Imaging in Parkinson's Disease 254
4. Molecular Imaging of the Noradrenaline Transporter 255

5. Imaging the Noradrenaline Transporter in Parkinson's Disease 258
6. Imaging of Cardiac Noradrenergic Denervation 262
7. Adrenoceptors in Parkinson's Disease 262
8. Conclusion 266
Financial support 266
References 266
Further Reading 274

9. Molecular Imaging of Opioid System in Idiopathic Parkinson's Disease 275

Stephane Thobois, Christine Brefel-Courbon, Didier Le Bars, and Véronique Sgambato-Faure

1. Anatomy of the Opioid System 276
2. PET Imaging of the Opioid System 278
3. General Statement on the Role of Opioid System in Parkinson's Disease 281
4. What Is Known About Opioid System Dysfunction in Parkinson's Disease: Clinical and PET Imaging Evidence 282
5. Imaging of the Opioid System in Parkinson's Disease: Perspectives 284
6. Physiological and Pathological Role of the Opioid System Outside Parkinson's Disease: Insights From PET Imaging Studies 286
7. Conclusion 295
References 295

10. Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease 305

Roberto Cilia

1. The Brain Endocannabinoid System 306
2. The Brain Endocannabinoid System in Idiopathic Parkinson's Disease 316
3. Molecular Imaging of the Cannabinoid System 325
4. Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease 331
References 335
Further Reading 344

11. Molecular Imaging of Neuroinflammation in Idiopathic Parkinson's Disease 347

Andreas-Antonios Roussakis and Paola Piccini

1. Introduction 348
2. Phenotypes of Microglia 349

3. Molecular Imaging of Microglia 351
4. Molecular Imaging of Astrocytes 356
5. Challenges of Future Research 358
References 359
Further Reading 363

12. Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease 365

Christine Ghadery, Mikaeel Valli, Alexander Mihaescu, Rebecca Strafella, Irene Navalpotro, Jinhee Kim, and Antonio P. Strafella

1. Introduction 366
2. Spectrum of Addictive Behavior in PD 367
3. Epidemiology 372
4. Pathophysiology 378
5. Molecular Imaging 381
6. Clinical Assessment and Management 392
7. Conclusion 395
Acknowledgments 396
References 396

13. Structural MRI in Idiopathic Parkinson's Disease 405

Rosa De Micco, Antonio Russo, and Alessandro Tessitore

1. Introduction 406
2. Diffusion MRI Studies 409
3. Structural Imaging of the Gray Matter Integrity 417
4. Neuromelanin-Sensitive MRI Studies 425
5. Conclusions 427
References 427
Further Reading 438

14. Functional MRI in Idiopathic Parkinson's Disease 439

Massimo Filippi, Sarasso Elisabetta, Noemi Piramide, and Federica Agosta

1. Introduction 440
2. fMRI to Assess Brain Functional Connectivity and Activity 440
3. Resting State Functional MRI 441
4. Task-Based Functional MRI 451
5. Conclusions 459
References 460